Arax Advisory Partners’s Dr. Reddy's Laboratories RDY Stock Holding History

Arax Advisory Partners’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.8K	Sell	2,883 -345	-11%	-$4.65K	﹤0.01%	3418
2026 Q1	$44.7K	Sell	3,228 -8,923	-73%	-$124K	﹤0.01%	1736
2025 Q4	$171K	Buy	12,151 +10,678	+725%	+$150K	0.01%	1103
2025 Q3	$20.6K	Buy	1,473 +558	+61%	+$8.03K	﹤0.01%	2252
2025 Q2	$25.1K	Buy	915 +540	+144%	+$7.71K	﹤0.01%	1555
2025 Q1	$4.95K	Buy	+375	New	+$5.17K	﹤0.01%	1781
2018 Q3	–	Sell	-535	Closed	-$3K	–	708
2018 Q2	$3K	Sell	535 -350	-40%	-$2.21K	﹤0.01%	425
2018 Q1	$5K	Buy	885 +145	+20%	+$1.02K	﹤0.01%	378
2017 Q4	$5K	Buy	740 +360	+95%	+$2.59K	﹤0.01%	378
2017 Q3	$2K	Buy	380 +35	+10%	+$252	﹤0.01%	425
2017 Q2	$3K	Sell	345 -360	-51%	-$2.93K	﹤0.01%	424
2017 Q1	$5K	Sell	705 -550	-44%	-$4.75K	﹤0.01%	360
2016 Q4	$11K	Buy	+1,255	New	+$11.7K	0.01%	316

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Arax Advisory Partners's RDY Position: Q2 2026 in Review

Arax Advisory Partners reduced its Dr. Reddy's Laboratories (RDY) stake by 11% in Q2 2026, selling an estimated $4.65K and leaving 2,883 shares worth $41.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3418.

Arax Advisory Partners first reported a position in RDY in Q4 2016 and has held it in 13 quarters since. The position peaked at $171K in Q4 2025. 238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

Arax Advisory Partners held 2,883 shares of Dr. Reddy's Laboratories worth $41.8K as of Q2 2026.
Arax Advisory Partners sold 345 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $4.65K.
Dr. Reddy's Laboratories made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3418 holding.
Arax Advisory Partners first reported a position in Dr. Reddy's Laboratories in Q4 2016 and has held it in 13 quarters since.
Arax Advisory Partners's Dr. Reddy's Laboratories position peaked at $171K in Q4 2025.
238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.